Decentralized clinical trials are on the rise in the EU and the UK. This month, new EU level guidance on how to conduct them has supplemented existing guidance on the topic. Zina Chatzidimitriadou, Lauren Cuyvers and Bronwyn Tonelli give seven considerations for decentralized trial sponsors in the region.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.png00Lauren Cuyvershttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngLauren Cuyvers2022-12-22 11:08:102025-09-26 16:11:08Navigating Decentralized Clinical Trials In the EU and the UK
The Biden administration is conducting investigations into potential antitrust violations to which the life sciences industry may be particularly vulnerable because having board members sit on more than one company is relatively common. Benjamin Nagin and Kristina Gliklad explain.
https://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/05/GLS-Blog_Generic-imagery-10.png606833Benjamin Naginhttps://goodlifesci.sidley.com/wp-content/uploads/sites/6/2022/03/sidleyLogo-e1643922598198.pngBenjamin Nagin2022-11-28 11:04:212025-09-26 16:11:22The U.S. Department of Justice may clamp down on life sciences companies that share board members with alleged competitors
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Navigating Decentralized Clinical Trials In the EU and the UK
Decentralized clinical trials are on the rise in the EU and the UK. This month, new EU level guidance on how to conduct them has supplemented existing guidance on the topic. Zina Chatzidimitriadou, Lauren Cuyvers and Bronwyn Tonelli give seven considerations for decentralized trial sponsors in the region.
Lauren Cuyvers
Brussels
lcuyvers@sidley.com
Bronwyn Tonelli
Trainee Solicitor
btonelli@sidley.com
Zina Chatzidimitriadou
London
zchatzidimitriadou@sidley.com
The U.S. Department of Justice may clamp down on life sciences companies that share board members with alleged competitors
The Biden administration is conducting investigations into potential antitrust violations to which the life sciences industry may be particularly vulnerable because having board members sit on more than one company is relatively common. Benjamin Nagin and Kristina Gliklad explain.
Benjamin Nagin
New York
bnagin@sidley.com
Kristina Gliklad
New York
kgliklad@sidley.com
Resources
Upcoming Events
Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions – Program and Lunch
Connecting Clusters of Excellence: Europe as Your Gateway to Global Success
Archives
Categories